Baxter Gets Pumped Up

It appears that Baxter's (NYSE: BAX  ) two FDA recalls have not affected the financials: The medical-device maker just posted a stellar quarter. But what's to become of that hoard of money it has sitting around?

Adjusted earnings per share rose 23% year over year for the quarter on just 8% growth in sales. Where did the rest on the bottom-line growth come from? Margins, my friend, margins -- oh, and a stock buyback to the tune of $827 million helped lower the earnings-per-share denominator.

The gross margin climbed 250 basis points to 50%, thanks to increasing sales of high-margin products and services, greater efficiency in manufacturing, and subsequent better prices -- especially for plasma-based products. As you can see below, an increasingly improved gross margin has been the trend for the company over the past year and a half -- during which time it's also been keeping sales, general, and administrative costs relatively in check.

Q1 2006

Q2 2006

Q3 2006

Q4 2006

Q1 2007

Q2 2007

Q3 2007

Gross Margin








SG&A Margin








Q1 2006-Q2 2007 figures are trailing-12-month values, as indicated by Capital IQ, a division of Standard & Poor's. Figures for Q3 2007 were calculated by the author.

Baxter's bioscience division continues to be on fire. Year-over-year sales growth of 14% included transferring back international marketing rights for the BeneFIX drug to Wyeth (NYSE: WYE  ) . Excluding those sales from both quarters, BioSciences' sales grew a whopping 19%.

In other drug-therapy news, Baxter announced during the quarter that it will form a new collaboration with Halozyme Therapeutics (Nasdaq: HALO  ) to develop a subcutaneous delivery for Gamaguard, its intravenous immunoglobulin (IVIG) product. A subcutaneous injection would make the product more patient-friendly and might be especially useful if Baxter is able to get Gamaguard approved for use in Alzheimer's patients.

Baxter is sitting on a big wad of cash. Management mentioned that although it's interested in using some of that money to buy companies, it's not likely to make any "large-scale" acquisitions. That probably means Baxter won't go around buying companies like they're a dime a dozen, the way Inverness Medical Innovations (AMEX: IMA  ) has done over the past year and a half. That's a good thing. But I continue to think that Baxter needs to do something with its money. Share buybacks are all well and good, but as the stock price continues to appreciate, other places for the cash look as though they'd be a better investment of stockholders' equity.

Read/Post Comments (0) | Recommend This Article (5)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 538885, ~/Articles/ArticleHandler.aspx, 10/27/2016 2:48:57 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,209.91 10.58 0.06%
S&P 500 2,137.95 -1.48 -0.07%
NASD 5,229.37 -20.90 -0.40%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/27/2016 2:33 PM
BAX $46.97 Down -0.47 -0.99%
Baxter CAPS Rating: ****
WYE.DL $0.00 Down +0.00 +0.00%
Wyeth CAPS Rating: ***